Simplex Trading
MLYS icon

Simplex Trading’s Mineralys Therapeutics MLYS Stock Holding History

Simplex Trading’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
38,900
+33,000
+559% +$905K ﹤0.01% 2723
2026
Q1 		$160K Buy
5,900
+1,800
+44% +$52.8K ﹤0.01% 4570
2025
Q4 		$149K Sell
4,100
-14,100
-77% -$565K ﹤0.01% 4541
2025
Q3 		$690K Buy
+18,200
New +$394K ﹤0.01% 3444
2025
Q2 		– Sell
-94,100
Closed -$1.49M – 9328
2025
Q1 		$1.49M Buy
94,100
+93,400
+13,343% +$1.07M ﹤0.01% 2320
2024
Q4 		$8K Hold
700
– – ﹤0.01% 7345
2024
Q3 		$8K Buy
+700
New +$8.47K ﹤0.01% 7344

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Simplex Trading's MLYS Position: Q2 2026 in Review

Simplex Trading increased its Mineralys Therapeutics (MLYS) stake by 84% in Q2 2026, buying an estimated $450K and bringing the position to 35,979 shares worth $971K. The position accounts for ﹤0.01% of the portfolio, ranked #2812.

Simplex Trading first reported a position in MLYS in Q3 2024 and has held it in 7 quarters since. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Simplex Trading held 35,979 shares of Mineralys Therapeutics worth $971K as of Q2 2026.
  • Simplex Trading bought 16,417 Mineralys Therapeutics shares in Q2 2026, an estimated $450K.
  • Mineralys Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #2812 holding.
  • Simplex Trading first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.